Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

NCT02493517 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
128
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Ipsen